Effects of niosomal cisplatin and combination of the same with theophylline and with activated macrophages in murine B16F10 melanoma model
The use of cisplatin is limited due to its certain toxic effects. In the present study niosomes of cisplatin by using span 60 and cholesterol were prepared and investigated for antimetastatic activity in experimental metastatic model of B16F10 melanoma. Theophylline and its combination effect with f...
Gespeichert in:
| Veröffentlicht in: | Cancer biotherapy & radiopharmaceuticals 2002-04, Vol.17 (2), p.183-192 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 192 |
|---|---|
| container_issue | 2 |
| container_start_page | 183 |
| container_title | Cancer biotherapy & radiopharmaceuticals |
| container_volume | 17 |
| creator | GUDE, R. P JADHAV, M. G RAO, S. G. A JAGTAP, A. G |
| description | The use of cisplatin is limited due to its certain toxic effects. In the present study niosomes of cisplatin by using span 60 and cholesterol were prepared and investigated for antimetastatic activity in experimental metastatic model of B16F10 melanoma. Theophylline and its combination effect with free cisplatin and niosomal cisplatin were also carried out in the same model. The effect of treatment with activated macrophages alone and in combination with cisplatin, theophylline and niosomal cisplatin was also observed. Treatment with niosomal cisplatin (1 mg/kg) and combination of the same with theophylline (15 mg/kg) showed significant reduction in the number of lung nodules as compared to untreated control as well as with free cisplatin (1 mg/kg). The treatment with activated macrophages (activated by using Muramyl dipeptide) significantly reduced the secondary growth of tumor in lung. Niosomal cisplatin showed a significant protection against weight loss and bone marrow toxicity as compared to free cisplatin. These results suggest that cisplatin encapsulated in niosomes has significant antimetastatic activity and reduced toxicities than that of free cisplatin. However theophylline failed to show antimetastatic effect alone or in combination with cisplatin or with activated macrophages. |
| doi_str_mv | 10.1089/108497802753773801 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_204209048</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1149694071</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-e3536fdad82b687684822eeeecbd88eb993593a13030f14ea1e077560c9bd0fe3</originalsourceid><addsrcrecordid>eNplkMFu1DAQhi0EoqXwAhyQhcQxMLbj2DlC1QJSJS5wjibOmE0V20ucBfUVeGpm25V6wAd7ZvTNP55fiNcK3ivw_Qe-2t550M4a54wH9UScK2td473VTzlmoGHCnokXtd4CQAedey7OlAYDSulz8fcqRgpblSXKPJdaEi4yzHW_4DZniXmSoaRxzpyWfKS2HcmKieSfedsds7Lf3S3LnOmevq9i2ObfuNEkE4aVAfxJVbJeOqxH8JPqrhXIRAtmnihTmWh5KZ5FXCq9Or0X4sf11ffLL83Nt89fLz_eNMHYbmvIWNPFCSevx867zrdea-ITxsl7Gvve2N6gMrxiVC2hInDOdhD6cYJI5kK8fdDdr-XXgeo23JbDmnnkoKHV0EPrGdIPEH-_1pXisF_nhOvdoGA4uj_87z43vTkpH8ZE02PLyW4G3p0ArAGXuGJmrx-5VnnXstg_P02Nbw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>204209048</pqid></control><display><type>article</type><title>Effects of niosomal cisplatin and combination of the same with theophylline and with activated macrophages in murine B16F10 melanoma model</title><source>Mary Ann Liebert Online Subscription</source><source>MEDLINE</source><creator>GUDE, R. P ; JADHAV, M. G ; RAO, S. G. A ; JAGTAP, A. G</creator><creatorcontrib>GUDE, R. P ; JADHAV, M. G ; RAO, S. G. A ; JAGTAP, A. G</creatorcontrib><description>The use of cisplatin is limited due to its certain toxic effects. In the present study niosomes of cisplatin by using span 60 and cholesterol were prepared and investigated for antimetastatic activity in experimental metastatic model of B16F10 melanoma. Theophylline and its combination effect with free cisplatin and niosomal cisplatin were also carried out in the same model. The effect of treatment with activated macrophages alone and in combination with cisplatin, theophylline and niosomal cisplatin was also observed. Treatment with niosomal cisplatin (1 mg/kg) and combination of the same with theophylline (15 mg/kg) showed significant reduction in the number of lung nodules as compared to untreated control as well as with free cisplatin (1 mg/kg). The treatment with activated macrophages (activated by using Muramyl dipeptide) significantly reduced the secondary growth of tumor in lung. Niosomal cisplatin showed a significant protection against weight loss and bone marrow toxicity as compared to free cisplatin. These results suggest that cisplatin encapsulated in niosomes has significant antimetastatic activity and reduced toxicities than that of free cisplatin. However theophylline failed to show antimetastatic effect alone or in combination with cisplatin or with activated macrophages.</description><identifier>ISSN: 1084-9785</identifier><identifier>EISSN: 1557-8852</identifier><identifier>DOI: 10.1089/108497802753773801</identifier><identifier>PMID: 12030112</identifier><identifier>CODEN: CBRAFJ</identifier><language>eng</language><publisher>Larchmont, NY: Liebert</publisher><subject>Animals ; Antineoplastic agents ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Body Weight ; Cisplatin - administration & dosage ; Combined Modality Therapy ; Combined treatments (chemotherapy of immunotherapy associated with an other treatment) ; Female ; Leukocyte Count ; Liposomes ; Macrophage Activation ; Macrophages, Peritoneal - physiology ; Male ; Medical sciences ; Melanoma, Experimental - pathology ; Melanoma, Experimental - secondary ; Melanoma, Experimental - therapy ; Mice ; Mice, Inbred C57BL ; Neoplasm Transplantation ; Pharmacology. Drug treatments ; Theophylline - administration & dosage ; Tumor Cells, Cultured</subject><ispartof>Cancer biotherapy & radiopharmaceuticals, 2002-04, Vol.17 (2), p.183-192</ispartof><rights>2002 INIST-CNRS</rights><rights>Copyright Mary Ann Liebert Inc. Apr 2002</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-e3536fdad82b687684822eeeecbd88eb993593a13030f14ea1e077560c9bd0fe3</citedby><cites>FETCH-LOGICAL-c356t-e3536fdad82b687684822eeeecbd88eb993593a13030f14ea1e077560c9bd0fe3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,3029,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14187477$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12030112$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>GUDE, R. P</creatorcontrib><creatorcontrib>JADHAV, M. G</creatorcontrib><creatorcontrib>RAO, S. G. A</creatorcontrib><creatorcontrib>JAGTAP, A. G</creatorcontrib><title>Effects of niosomal cisplatin and combination of the same with theophylline and with activated macrophages in murine B16F10 melanoma model</title><title>Cancer biotherapy & radiopharmaceuticals</title><addtitle>Cancer Biother Radiopharm</addtitle><description>The use of cisplatin is limited due to its certain toxic effects. In the present study niosomes of cisplatin by using span 60 and cholesterol were prepared and investigated for antimetastatic activity in experimental metastatic model of B16F10 melanoma. Theophylline and its combination effect with free cisplatin and niosomal cisplatin were also carried out in the same model. The effect of treatment with activated macrophages alone and in combination with cisplatin, theophylline and niosomal cisplatin was also observed. Treatment with niosomal cisplatin (1 mg/kg) and combination of the same with theophylline (15 mg/kg) showed significant reduction in the number of lung nodules as compared to untreated control as well as with free cisplatin (1 mg/kg). The treatment with activated macrophages (activated by using Muramyl dipeptide) significantly reduced the secondary growth of tumor in lung. Niosomal cisplatin showed a significant protection against weight loss and bone marrow toxicity as compared to free cisplatin. These results suggest that cisplatin encapsulated in niosomes has significant antimetastatic activity and reduced toxicities than that of free cisplatin. However theophylline failed to show antimetastatic effect alone or in combination with cisplatin or with activated macrophages.</description><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Body Weight</subject><subject>Cisplatin - administration & dosage</subject><subject>Combined Modality Therapy</subject><subject>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</subject><subject>Female</subject><subject>Leukocyte Count</subject><subject>Liposomes</subject><subject>Macrophage Activation</subject><subject>Macrophages, Peritoneal - physiology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Melanoma, Experimental - pathology</subject><subject>Melanoma, Experimental - secondary</subject><subject>Melanoma, Experimental - therapy</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Neoplasm Transplantation</subject><subject>Pharmacology. Drug treatments</subject><subject>Theophylline - administration & dosage</subject><subject>Tumor Cells, Cultured</subject><issn>1084-9785</issn><issn>1557-8852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNplkMFu1DAQhi0EoqXwAhyQhcQxMLbj2DlC1QJSJS5wjibOmE0V20ucBfUVeGpm25V6wAd7ZvTNP55fiNcK3ivw_Qe-2t550M4a54wH9UScK2td473VTzlmoGHCnokXtd4CQAedey7OlAYDSulz8fcqRgpblSXKPJdaEi4yzHW_4DZniXmSoaRxzpyWfKS2HcmKieSfedsds7Lf3S3LnOmevq9i2ObfuNEkE4aVAfxJVbJeOqxH8JPqrhXIRAtmnihTmWh5KZ5FXCq9Or0X4sf11ffLL83Nt89fLz_eNMHYbmvIWNPFCSevx867zrdea-ITxsl7Gvve2N6gMrxiVC2hInDOdhD6cYJI5kK8fdDdr-XXgeo23JbDmnnkoKHV0EPrGdIPEH-_1pXisF_nhOvdoGA4uj_87z43vTkpH8ZE02PLyW4G3p0ArAGXuGJmrx-5VnnXstg_P02Nbw</recordid><startdate>20020401</startdate><enddate>20020401</enddate><creator>GUDE, R. P</creator><creator>JADHAV, M. G</creator><creator>RAO, S. G. A</creator><creator>JAGTAP, A. G</creator><general>Liebert</general><general>Mary Ann Liebert, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7T5</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20020401</creationdate><title>Effects of niosomal cisplatin and combination of the same with theophylline and with activated macrophages in murine B16F10 melanoma model</title><author>GUDE, R. P ; JADHAV, M. G ; RAO, S. G. A ; JAGTAP, A. G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-e3536fdad82b687684822eeeecbd88eb993593a13030f14ea1e077560c9bd0fe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Body Weight</topic><topic>Cisplatin - administration & dosage</topic><topic>Combined Modality Therapy</topic><topic>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</topic><topic>Female</topic><topic>Leukocyte Count</topic><topic>Liposomes</topic><topic>Macrophage Activation</topic><topic>Macrophages, Peritoneal - physiology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Melanoma, Experimental - pathology</topic><topic>Melanoma, Experimental - secondary</topic><topic>Melanoma, Experimental - therapy</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Neoplasm Transplantation</topic><topic>Pharmacology. Drug treatments</topic><topic>Theophylline - administration & dosage</topic><topic>Tumor Cells, Cultured</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GUDE, R. P</creatorcontrib><creatorcontrib>JADHAV, M. G</creatorcontrib><creatorcontrib>RAO, S. G. A</creatorcontrib><creatorcontrib>JAGTAP, A. G</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Cancer biotherapy & radiopharmaceuticals</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GUDE, R. P</au><au>JADHAV, M. G</au><au>RAO, S. G. A</au><au>JAGTAP, A. G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of niosomal cisplatin and combination of the same with theophylline and with activated macrophages in murine B16F10 melanoma model</atitle><jtitle>Cancer biotherapy & radiopharmaceuticals</jtitle><addtitle>Cancer Biother Radiopharm</addtitle><date>2002-04-01</date><risdate>2002</risdate><volume>17</volume><issue>2</issue><spage>183</spage><epage>192</epage><pages>183-192</pages><issn>1084-9785</issn><eissn>1557-8852</eissn><coden>CBRAFJ</coden><abstract>The use of cisplatin is limited due to its certain toxic effects. In the present study niosomes of cisplatin by using span 60 and cholesterol were prepared and investigated for antimetastatic activity in experimental metastatic model of B16F10 melanoma. Theophylline and its combination effect with free cisplatin and niosomal cisplatin were also carried out in the same model. The effect of treatment with activated macrophages alone and in combination with cisplatin, theophylline and niosomal cisplatin was also observed. Treatment with niosomal cisplatin (1 mg/kg) and combination of the same with theophylline (15 mg/kg) showed significant reduction in the number of lung nodules as compared to untreated control as well as with free cisplatin (1 mg/kg). The treatment with activated macrophages (activated by using Muramyl dipeptide) significantly reduced the secondary growth of tumor in lung. Niosomal cisplatin showed a significant protection against weight loss and bone marrow toxicity as compared to free cisplatin. These results suggest that cisplatin encapsulated in niosomes has significant antimetastatic activity and reduced toxicities than that of free cisplatin. However theophylline failed to show antimetastatic effect alone or in combination with cisplatin or with activated macrophages.</abstract><cop>Larchmont, NY</cop><pub>Liebert</pub><pmid>12030112</pmid><doi>10.1089/108497802753773801</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1084-9785 |
| ispartof | Cancer biotherapy & radiopharmaceuticals, 2002-04, Vol.17 (2), p.183-192 |
| issn | 1084-9785 1557-8852 |
| language | eng |
| recordid | cdi_proquest_journals_204209048 |
| source | Mary Ann Liebert Online Subscription; MEDLINE |
| subjects | Animals Antineoplastic agents Antineoplastic Agents - therapeutic use Biological and medical sciences Body Weight Cisplatin - administration & dosage Combined Modality Therapy Combined treatments (chemotherapy of immunotherapy associated with an other treatment) Female Leukocyte Count Liposomes Macrophage Activation Macrophages, Peritoneal - physiology Male Medical sciences Melanoma, Experimental - pathology Melanoma, Experimental - secondary Melanoma, Experimental - therapy Mice Mice, Inbred C57BL Neoplasm Transplantation Pharmacology. Drug treatments Theophylline - administration & dosage Tumor Cells, Cultured |
| title | Effects of niosomal cisplatin and combination of the same with theophylline and with activated macrophages in murine B16F10 melanoma model |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T05%3A35%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20niosomal%20cisplatin%20and%20combination%20of%20the%20same%20with%20theophylline%20and%20with%20activated%20macrophages%20in%20murine%20B16F10%20melanoma%20model&rft.jtitle=Cancer%20biotherapy%20&%20radiopharmaceuticals&rft.au=GUDE,%20R.%20P&rft.date=2002-04-01&rft.volume=17&rft.issue=2&rft.spage=183&rft.epage=192&rft.pages=183-192&rft.issn=1084-9785&rft.eissn=1557-8852&rft.coden=CBRAFJ&rft_id=info:doi/10.1089/108497802753773801&rft_dat=%3Cproquest_cross%3E1149694071%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=204209048&rft_id=info:pmid/12030112&rfr_iscdi=true |